Taxotere®, Followed by Myocet® and Cyclophosphamide First Line Treatment in HER2 Neg Breast Cancer

Ainda não traduzido Ainda não traduzido
Categoria Primary study
Registry of Trialsclinicaltrials.gov
Year 2008

This article is not included in any systematic review

Loading references information
The purpose of this study is to determine how many pathological complete responses are achieved in patients treated with taxotere® (T) followed by Myocet® (M)and Cyclophosphamide (MC) first line treatment in HER2 negative brest cancer patients.
Epistemonikos ID: 70cf363365d66f3a8be8ad01c9b3a86678e6c90a
First added on: May 05, 2024